pSivida Corp. (PSDV) to Release Quarterly Earnings on Tuesday
pSivida Corp. (NASDAQ:PSDV) is scheduled to announce its earnings results after the market closes on Tuesday, November 7th. Analysts expect the company to announce earnings of ($0.15) per share for the quarter.
pSivida Corp. (NASDAQ:PSDV) last posted its earnings results on Monday, September 11th. The company reported ($0.16) EPS for the quarter, hitting analysts’ consensus estimates of ($0.16). pSivida Corp. had a negative net margin of 245.19% and a negative return on equity of 134.34%. The firm had revenue of $0.70 million during the quarter, compared to analysts’ expectations of $0.48 million.
pSivida Corp. (NASDAQ:PSDV) opened at $1.23 on Friday. pSivida Corp. has a 52 week low of $1.03 and a 52 week high of $2.45.
Separately, HC Wainwright set a $5.00 target price on shares of pSivida Corp. and gave the company a “buy” rating in a research report on Tuesday, July 11th. Five analysts have rated the stock with a buy rating, The company currently has a consensus rating of “Buy” and an average price target of $8.60.
TRADEMARK VIOLATION NOTICE: “pSivida Corp. (PSDV) to Release Quarterly Earnings on Tuesday” was first posted by Daily Political and is the sole property of of Daily Political. If you are viewing this report on another publication, it was stolen and reposted in violation of international trademark & copyright legislation. The correct version of this report can be viewed at https://www.dailypolitical.com/2017/11/05/psivida-corp-psdv-to-release-quarterly-earnings-on-tuesday.html.
pSivida Corp. Company Profile
pSivida Corp. develops drug delivery products primarily for the treatment of chronic eye diseases. The Company operates through the biotechnology sector segment. The Company has developed three products for treatment of back-of-the-eye diseases, which include Medidur for posterior segment uveitis, its lead product candidate that is in pivotal Phase III clinical trials; ILUVIEN for diabetic macular edema (DME), its lead licensed product that is sold in the United States and European Union (EU) countries, and Retisert.
Receive News & Ratings for pSivida Corp. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for pSivida Corp. and related companies with MarketBeat.com's FREE daily email newsletter.